SEARCH

SEARCH BY CITATION

References

  • 1
    Menon DV, Arbique D, Wang Z, et al. Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. J Clin Endocrinol Metab. 2009;94:13611366.
  • 2
    McCormack PL, Wagstaff AJ. Lacidipine: a review of its use in the management of hypertension. Drugs. 2003;63:23272356.
  • 3
    Fu Q, Zhang R, Witkowski S, et al. Persistent sympathetic activation during chronic antihypertensive therapy: a potential mechanism for long term morbidity? Hypertension. 2005;45:513521.
  • 4
    Wustmann K, Kucera JP, Scheffers I, et al. Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension. 2009;54:530536.
  • 5
    Bilgutay AM, Lillehei CW. Treatment of hypertension with an implantable electronic device. JAMA. 1965;191:113117.
  • 6
    Braunwald E, Epstein SE, Glick G, et al. Relief of angina pectoris by electrical stimulation of the carotid-sinus nerves. N Engl J Med. 1967;277:12781283.
  • 7
    Lohmeier TE, Dwyer TM, Hildebrand DA, et al. Influence of prolonged baroreflex activation on arterial pressure in angiotensin hypertension. Hypertension. 2005;46:11942000.
  • 8
    Lohmeier TE, Hildebrandt DA, Dwyer TM, et al. Renal denervation does not abolish sustained baroreflex-mediated reductions in arterial pressure. Hypertension. 2007;49:373379.
  • 9
    Lohmeier TE, Dwyer TM, Irwin ED, et al. Prolonged activation of the baroreflex abolishes obesity-induced hypertension. Hypertension. 2007;49:13071314.
  • 10
    Lohmeier TE, Hildebrant DA, Dwyer TM, et al. Prolonged activation of the baroreflex abolishes reduced kidney mass, salt-induced hypertension. Hypertension. 2007;50:e85.
  • 11
    Gupta RC, Imai M, Cody RJ, et al. Baroreflex activation therapy normalizes gene expression of components of the beta-adrenergic receptor signaling pathway in LV myocardium of dogs with chronic heart failure. Eur Heart J. 2007;28 (Abstract Supplement):818819.
  • 12
    Zucker IH, Hckley JF, Cornish KG, et al. Chronic baroreceptor activation enhances survival in dogs with pacing-induced heart failure. Hypertension. 2007;50:904910.
  • 13
    Scheffers I, Schmidli J, Kroon AA, et al. Sustained blood pressure reduction by baroreflex hypertension therapy with a chronically implanted system: 3-year data from the Rheos DEBuT study in patients with resistant hypertension. J Hypertens. 2009;27(suppl). In press.
  • 14
    Bisognano J, De Leeuw P, Irwin E, et al. Long term baroreflex hypertension therapy significantly lowers ambulatory blood pressures in patients with resistant hypertension. J Clin Hypertens. 2008;10:271.
  • 15
    Bisognano JD, De Leeuw P, Bach DS, et al. Improved cardiac structure and function in early-stage heart failure and chronic treatment using an implantable device: results from European and United States trials of the Rheos System. J Card Fail. 2008;14:S48.
  • 16
    Sica D, Rothstein M, Bisognano JD, et al. Baroreflex activation therapy preserves eGFR in hypertensive patients with stage 2 and 3 chronic kidney disease: results from european and United States trials of the Rheos® system. J Am Soc Nephrol. 2009;20.